



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 13th January, 2026.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 531569

Sub: Investor Presentation for the Third Quarter and Nine months ended on ended
December 31, 2025.

Dear Sir/ Madam,

Please find enclosed herewith Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the Third Quarter and Nine months ended on December 31, 2025.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam
Company Secretary Cum Compliance Officer



SANJIVANI
PARANTERAL LTD

INVESTOR PRESENTATION

Q3 FY26





Table of Contents

05

Market Overview

08

About The Company

14

Manufacturing
Facilities

17

CDMO Key Clients

19

Company's Segment &
Revenue Mix

23

Global Footprint

25

Product Portfolio

29

Financials

37

Stock Information



Key Financial Highlights (Standalone)

Q3 FY26



Revenue from Operations
(up 20.3% Y-o-Y)

INR 208.6 mn



EBITDA*
(up by 35.7% Y-o-Y)

INR 38.8 mn



PAT
(up by 37.8% Y-o-Y)

INR 26.2 mn



Domestic & Export
(share in revenue)

23.1% & 76.9%

*EBITDA: includes other income

Key Financial Highlights (Standalone)

9M FY26



Revenue from Operations
(up 4.5% Y-o-Y)

INR 542.5 mn



EBITDA*
(up 5.3% Y-o-Y)

INR 89.8 mn



PAT
(up 1.3% Y-o-Y)

INR 59.9 mn



Domestic & Export
(share in revenue)

22.8% & 77.2%

*EBITDA: includes other income



SANJIVANI
PARANTERAL LTD

MARKET OVERVIEW




Global Medicine Market

Use of medicines region wise, Defined Daily Doses (DDD)


Country Name/Year	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E	2027E	2028E	CAGR 2024-2028
Asia-Pacific	451	461	477	507	547	538	559	580	598	618	637	3.4%
Latin America	342	357	438	447	448	461	473	484	489	496	506	1.9%
Western Europe	435	445	444	448	469	463	470	476	481	485	488	1.1%
India	354	359	370	400	390	399	412	428	443	458	474	3.5%
Africa & Middle East	385	395	393	428	425	410	413	424	434	442	451	1.9%
Eastern Europe	332	339	341	358	369	362	370	377	384	388	391	1.6%
China	255	279	271	301	308	308	323	337	349	359	369	3.7%
North America	270	272	270	281	290	290	294	299	303	306	309	1.3%
Japan	141	143	141	145	147	148	149	151	152	152	153	0.6%
Total	2,964	3,049	3,144	3,316	3,394	3,378	3,465	3,556	3,633	3,704	3,778	

Source: IQVIA Institute, Dec 2023.


**Defined Daily Doses
(DDD) in billions**



**Global use of
medicines**



**Global spending
on medicine**



Source: IQVIA Institute, Dec 2023.



SANJIVANI
PARANTERAL LTD

ABOUT THE COMPANY



About Us



Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.



**WHO-GMP/
DIGEMID / DDA**

Certified
Plants



2

Manufacturing
Facilities



25

Countries
Geographical
Reach



~75%

Exports
Revenue



25+ years

Experience



**720
million**

Annual Tablet
Capacity



84 million

Annual Ampoules
Capacity



12 million

Annual Liquid
injectables Capacity



120 million

Annual B Lactam
Tablet Capacity



180 million

Annual B Lactam
Capsule Capacity



72 million


Annual Capsule
Capacity



48 million

Annual Vial
Capacity

Significant Milestones of Sanjivani Paranteral Ltd.



Vision of the Company



VISION

To be one of India's best research-based pharmaceutical companies, through focus on quality and customer satisfaction.

To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members.

To grow the company on the foundation of Passion, Performance & Partnership.



MISSION

Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities.



VALUES

1. Quality

Products that we are proud of

2. Customer Satisfaction

Ensuring customer delight


3. Growth for all stakeholders

Exceeding stakeholders' expectations is our success mantra

4. Professionalism

People you love to work with. A culture of innovative thinking, backed by disciplined execution

Sanjivani Paranteral's Competitive Advantage



Experienced Management



Mr. Ashwani Khemka
Chairman & Managing Director



Mr. Basant Srivastava
Director



Mr. Srivardhan Khemka
Executive Director



Mr. Abhay Shah
Independent Director



Ms. Monika A. Singhania
Independent Director



Mr. Pritesh Jain
Chief Financial Officer



MANUFACTURING FACILITIES



Manufacturing Plant – Alevia HealthCare, Czech Republic



IV Manufacturing Plant – SPL Infusion Private Limited, Pune





CDMO KEY CLIENTS



Injectables



Oral & Nutraceuticals






COMPANY'S SEGMENT & REVENUE MIX




Product Category Mix (%) | Standalone


Q3 FY26




Q3 FY25



9M FY26




9M FY25




Geographical Mix (%) | Standalone


Q3 FY26




Q3 FY25



9M FY26




9M FY25




Region-wise Mix (%)


Q3 FY26




Q3 FY25



9M FY26



9M FY25






GLOBAL FOOTPRINT



Global Footprint





PRODUCT PORTFOLIO



Product Portfolio



Product Portfolio

Urologics



Anesthetics



Anesthetics



Anti Convulsants



Anti Thyroid Agent



Anti Fungal



Anti Emetics



Anti Depressants



Anti Histamines



Anti Diabetic



Anti-lepemic Agent



Anti Fibrinolytics



Anti-bacterials



Anti-spasmodic



Anti Hypertensive Agent



Vitamin Supplement



Skeletal Muscle Relaxant



Analgesic & Anti Histaminic



Product Portfolio

Non-opioid Analgesics



Antacids



Antiseptics



Nsaids



Corticosteroids



Diuretics



Immunosuppressants



Narcotic



Hormone



Topical Corticosteroids



Anti Anxiety



Antibiotic



Antipsychotic



Anti Viral



Narcotics



Anti- Muscle Relaxant






FINANCIALS




Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


INJECTABLES



ORALS




NUTRACEUTICALS




Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


INJECTABLES



ORALS



NUTRACEUTICALS




Quarterly Financials

Revenue, EBITDA & Margin, PAT & Margin




INR Mn.


REVENUE*




EBITDA & EBITDA Margin**



PBT & PBT Margin



PAT & PAT Margin



*Revenue from Operations (excluding other income) **EBITDA: Including other income


Quarterly Financials

Revenue, EBITDA & Margin, PAT & Margin




INR Mn.


REVENUE*




EBITDA** & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin



*Revenue from Operations (excluding other income) **EBITDA: Including other income


Q3 FY26 Profit & Loss Statement

Particulars	Q3 FY26	Q3 FY25	YoY%	Q2 FY26	QoQ%	9MFY26	9MFY25	YoY%
Revenue From Operations	208.6	173.5	20.3%	155.0	34.6%	542.5	519.2	4.5%
Other Income	2.9	3.1	-6.8%	1.6	77.2%	4.9	7.9	-37.7%
Total Income	211.5	176.6	19.8%	156.6	35.1%	547.4	527.0	3.9%
COGS	141.9	99.3	42.9%	103.4	37.2%	356.4	310.9	14.6%
Gross Profit	69.7	77.3	-9.9%	53.3	30.9%	191.1	216.1	-11.6%
Gross Margin (%)	33.4%	44.6%	-1116 bps	34.4%	-96 bps	35.2%	41.6%	-641 bps
Employee Benefit Exp.	16.2	16.5	-1.3%	14.9	8.7%	46.4	43.9	5.7%
Other Expenses	14.6	32.2	-54.7%	14.2	2.7%	54.9	87.0	-36.9%
EBITDA incl. other income	38.8	28.6	35.7%	24.1	61.2%	89.8	85.3	5.3%
EBITDA Margin (%)	18.4%	16.2%	216 bps	15.4%	297 bps	16.4%	16.2%	22 bps
Depreciation	1.9	1.6	17.5%	1.7	10.9%	5.2	4.4	18.7%
Finance Cost	2.1	1.9	7.6%	0.5	320.6%	4.8	3.9	22.3%
PBT	34.9	25.1	39.0%	21.9	59.2%	79.8	77.0	3.7%
Tax	8.7	6.1	42.8%	5.5	57.6%	20.0	17.9	11.4%
PAT	26.2	19.0	37.8%	16.4	59.7%	59.9	59.1	1.3%
PAT Margin (%)	12.4%	10.7%	162 bps	10.5%	191 bps	10.9%	11.2%	-28 bps
Basic EPS (in Rs.)	2.13	1.62	31.1%	1.33	59.7%	4.87	5.06	-2.7%
Diluted EPS (in Rs.)	2.13	1.62		1.33		4.87	5.06	

Q3 FY26 Profit & Loss Statement (Consolidated)


Particulars	Q3 FY26	Q3 FY25	YoY%	Q2 FY26	QoQ%	9MFY26	9MFY25	YoY%
Revenue From Operations	220.6	173.5	27.2%	155	42.4%	554.5	519.2	6.8%
Other Income	3.0	3.1	-5.4%	1.6	80.0%	4.9	7.9	-37.1%
Total Income	223.6	176.6	26.6%	156.6	42.8%	559.5	527	6.2%
COGS	147.3	99.3	48.4%	103.4	42.6%	361.8	310.9	16.4%
Gross Profit	76.2	77.3	-1.4%	53.3	43.2%	197.6	216.1	-8.6%
Gross Margin (%)	34.6%	44.6%	-1001 bps	34.4%	19 bps	35.6%	41.6%	-599 bps
Employee Benefit Exp.	17.6	16.5	6.7%	14.9	17.5%	47.7	43.9	8.7%
Other Expenses	17.3	32.2	-46.2%	14.2	22.0%	57.7	87	-33.7%
EBITDA incl. other income	41.3	28.6	44.4%	24.1	71.6%	92.3	85.3	8.2%
EBITDA Margin (%)	18.5%	16.2%	229 bps	15.4%	310 bps	16.5%	16.2%	32 bps
Depreciation	2.3	1.6	43.0%	1.7	34.9%	5.6	4.4	28.0%
Finance Cost	2.1	1.9	7.6%	0.5	320.6%	4.8	3.9	22.3%
PBT	37.0	25.1	47.4%	21.9	68.7%	81.9	77.0	6.4%
Tax	9.2	6.1	51.0%	5.5	66.7%	20.5	17.9	14.2%
PAT	27.8	19.0	46.2%	16.4	69.4%	61.5	59.1	4.0%
PAT Margin (%)	12.4%	10.7%	167 bps	10.5%	196 bps	11.0%	11.2%	-23 bps
Basic EPS (in Rs.)	2.21	1.62	39.1%	1.33	69.4%	4.95	5.06	-0.1%
Diluted EPS (in Rs.)	2.21	1.62		1.33		4.95	5.06	

Long Term Growth Drivers




Stock Information

Shareholding Pattern % as on 31st December 2025



Stock Information (as on 31st December 2025)

Market Cap. (in Bn)	2.8
Stock Price	231
52 Week (High / Low)	383 / 182
BSE – Symbol	531569
Free Float (No. of Shares)	84,51,239
Average Daily Volume (3 months) - BSE	7600



:



THANK YOU

Sanjivani Paranteral Limited

205, P.N.Kothari Industrial Estate, L.B.S.
Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email: corporate@sanjivani.co.in